2025 Q2 -tulosraportti
221 päivää sitten
‧37 min
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·16 min sittenIf anyone should be in doubt, Circio's management is the absolute best in RNA research. ChatGbt provides a short summary of their competencies here: Here is a concise summary of the competencies in Circio's management and board of directors, which together cover the entire journey from laboratory research to billion-dollar deals in Big Pharma. Management Team (Daily operations) This team is responsible for technical development and commercial execution. Scientific Gravitas (Dr. Thomas B. Hansen & Dr. Victor Levitsky): They represent the absolute elite in RNA research and immunology. Hansen is the pioneer behind the technology, while Levitsky ensures that it can be used targeted against diseases. Strategic Execution (Dr. Erik D. Wiklund & Ola Melin): Wiklund brings "Big Pharma-logic" from McKinsey, while Melin ensures industrial scaling (CMC), so the product can actually be manufactured and approved. Board of Directors (Strategy and control) The board is composed to make the company "sale-ready" or ready for large licensing agreements. Deal-making and Exit Experience (Damian Marron & Dr. Lubor Gaal): Both have decades of experience in negotiating with the largest pharmaceutical companies and know precisely the metrics that trigger large acquisitions or partnerships. Protection and Finance (Diane Mellett & Thomas Falck): Mellett ensures that the company's intellectual property rights (patents) are bulletproof, while Falck manages the financial structure and investor relations. Technical backup (Robert Burns): Functions as a scientific guarantor, ensuring continuity in clinical decisions. In short: The management has invented and built the engine, while the board has the map and keys to drive it into the right negotiation rooms at Big Pharma.
·25 min sittenFor some investors, it's an important point to monitor whether management participates in share issues and holds shares in the company they lead/work for. For Circio's part, both CEO Erik Wiklund (both privately and through his company - 728.133 shares) and CTO Thomas Birkballe Hansen (315.600) have a good number of shares in the company. In other words, they are - in it to win it! So, we can check that off.
·58 min sittenIt's a bit of a shame to look forward all Easter to the stock market opening, because then the holiday is also over. But finally stock market day tomorrow and I'm super excited!
·1 t sitten · MuokattuUpdate - I am wiser now thanks to your answers. Many thanks 🙂 It is an old analysis. I have full confidence that this stock has a good future, but I do not understand the analysts' analysis of it. But does anyone have an explanation for this analysis?
·34 min sittenIt is impossible to provide a good guiding analysis here before we have received more info and updates from ongoing studies. Should CircVec also deliver strong results in a clinical phase, it will be almost impossible to find the right price for something as ground breaking and cutting edge as what they hopefully have managed/will manage to achieve. My point is that here it's about dropping price target analyses, because everyone will miss badly. Rather look at the fundamentals of the stock and trust the process. The finances are better than ever and they will most likely be financed far into a clinical phase which I believe will start in 2027. Then it matters little to me what the price is. In this stock, the fundamental factors are quite clear and evident for the next year, and that is all one needs to consider if one wants the most possible gain.- ·11 t sittenFrom Tekinvestor. People must take into account that Circio, until the completed emission in January, lived on student loans and a diet based on oatmeal and noodles. Only a couple of months have passed now where the company has shifted gears due to better financial leeway. In that regard, it will be particularly interesting to see what the company will present at ASGTC, as it still represents what the company has generated in new knowledge and data from the period of weak economy. So people can themselves ponder what can come ahead now that they can increase the pace of CircVec's development. Say what you will, but what Circio has achieved in recent years strongly impresses me. What they can accomplish with good finances and more hands is something to look forward to…
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q2 -tulosraportti
221 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 min sittenIf anyone should be in doubt, Circio's management is the absolute best in RNA research. ChatGbt provides a short summary of their competencies here: Here is a concise summary of the competencies in Circio's management and board of directors, which together cover the entire journey from laboratory research to billion-dollar deals in Big Pharma. Management Team (Daily operations) This team is responsible for technical development and commercial execution. Scientific Gravitas (Dr. Thomas B. Hansen & Dr. Victor Levitsky): They represent the absolute elite in RNA research and immunology. Hansen is the pioneer behind the technology, while Levitsky ensures that it can be used targeted against diseases. Strategic Execution (Dr. Erik D. Wiklund & Ola Melin): Wiklund brings "Big Pharma-logic" from McKinsey, while Melin ensures industrial scaling (CMC), so the product can actually be manufactured and approved. Board of Directors (Strategy and control) The board is composed to make the company "sale-ready" or ready for large licensing agreements. Deal-making and Exit Experience (Damian Marron & Dr. Lubor Gaal): Both have decades of experience in negotiating with the largest pharmaceutical companies and know precisely the metrics that trigger large acquisitions or partnerships. Protection and Finance (Diane Mellett & Thomas Falck): Mellett ensures that the company's intellectual property rights (patents) are bulletproof, while Falck manages the financial structure and investor relations. Technical backup (Robert Burns): Functions as a scientific guarantor, ensuring continuity in clinical decisions. In short: The management has invented and built the engine, while the board has the map and keys to drive it into the right negotiation rooms at Big Pharma.
- ·25 min sittenFor some investors, it's an important point to monitor whether management participates in share issues and holds shares in the company they lead/work for. For Circio's part, both CEO Erik Wiklund (both privately and through his company - 728.133 shares) and CTO Thomas Birkballe Hansen (315.600) have a good number of shares in the company. In other words, they are - in it to win it! So, we can check that off.
- ·58 min sittenIt's a bit of a shame to look forward all Easter to the stock market opening, because then the holiday is also over. But finally stock market day tomorrow and I'm super excited!
- ·1 t sitten · MuokattuUpdate - I am wiser now thanks to your answers. Many thanks 🙂 It is an old analysis. I have full confidence that this stock has a good future, but I do not understand the analysts' analysis of it. But does anyone have an explanation for this analysis?·34 min sittenIt is impossible to provide a good guiding analysis here before we have received more info and updates from ongoing studies. Should CircVec also deliver strong results in a clinical phase, it will be almost impossible to find the right price for something as ground breaking and cutting edge as what they hopefully have managed/will manage to achieve. My point is that here it's about dropping price target analyses, because everyone will miss badly. Rather look at the fundamentals of the stock and trust the process. The finances are better than ever and they will most likely be financed far into a clinical phase which I believe will start in 2027. Then it matters little to me what the price is. In this stock, the fundamental factors are quite clear and evident for the next year, and that is all one needs to consider if one wants the most possible gain.
- ·11 t sittenFrom Tekinvestor. People must take into account that Circio, until the completed emission in January, lived on student loans and a diet based on oatmeal and noodles. Only a couple of months have passed now where the company has shifted gears due to better financial leeway. In that regard, it will be particularly interesting to see what the company will present at ASGTC, as it still represents what the company has generated in new knowledge and data from the period of weak economy. So people can themselves ponder what can come ahead now that they can increase the pace of CircVec's development. Say what you will, but what Circio has achieved in recent years strongly impresses me. What they can accomplish with good finances and more hands is something to look forward to…
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
2025 Q2 -tulosraportti
221 päivää sitten
‧37 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2025 Q4 -tulosraportti 15.4. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q2 -tulosraportti 28.8.2025 | ||
2024 Q4 -tulosraportti 10.4.2025 | ||
2024 Q2 -tulosraportti 29.8.2024 | ||
2023 Q4 -tulosraportti 25.4.2024 | ||
2023 Q3 -tulosraportti 9.11.2023 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·16 min sittenIf anyone should be in doubt, Circio's management is the absolute best in RNA research. ChatGbt provides a short summary of their competencies here: Here is a concise summary of the competencies in Circio's management and board of directors, which together cover the entire journey from laboratory research to billion-dollar deals in Big Pharma. Management Team (Daily operations) This team is responsible for technical development and commercial execution. Scientific Gravitas (Dr. Thomas B. Hansen & Dr. Victor Levitsky): They represent the absolute elite in RNA research and immunology. Hansen is the pioneer behind the technology, while Levitsky ensures that it can be used targeted against diseases. Strategic Execution (Dr. Erik D. Wiklund & Ola Melin): Wiklund brings "Big Pharma-logic" from McKinsey, while Melin ensures industrial scaling (CMC), so the product can actually be manufactured and approved. Board of Directors (Strategy and control) The board is composed to make the company "sale-ready" or ready for large licensing agreements. Deal-making and Exit Experience (Damian Marron & Dr. Lubor Gaal): Both have decades of experience in negotiating with the largest pharmaceutical companies and know precisely the metrics that trigger large acquisitions or partnerships. Protection and Finance (Diane Mellett & Thomas Falck): Mellett ensures that the company's intellectual property rights (patents) are bulletproof, while Falck manages the financial structure and investor relations. Technical backup (Robert Burns): Functions as a scientific guarantor, ensuring continuity in clinical decisions. In short: The management has invented and built the engine, while the board has the map and keys to drive it into the right negotiation rooms at Big Pharma.
- ·25 min sittenFor some investors, it's an important point to monitor whether management participates in share issues and holds shares in the company they lead/work for. For Circio's part, both CEO Erik Wiklund (both privately and through his company - 728.133 shares) and CTO Thomas Birkballe Hansen (315.600) have a good number of shares in the company. In other words, they are - in it to win it! So, we can check that off.
- ·58 min sittenIt's a bit of a shame to look forward all Easter to the stock market opening, because then the holiday is also over. But finally stock market day tomorrow and I'm super excited!
- ·1 t sitten · MuokattuUpdate - I am wiser now thanks to your answers. Many thanks 🙂 It is an old analysis. I have full confidence that this stock has a good future, but I do not understand the analysts' analysis of it. But does anyone have an explanation for this analysis?·34 min sittenIt is impossible to provide a good guiding analysis here before we have received more info and updates from ongoing studies. Should CircVec also deliver strong results in a clinical phase, it will be almost impossible to find the right price for something as ground breaking and cutting edge as what they hopefully have managed/will manage to achieve. My point is that here it's about dropping price target analyses, because everyone will miss badly. Rather look at the fundamentals of the stock and trust the process. The finances are better than ever and they will most likely be financed far into a clinical phase which I believe will start in 2027. Then it matters little to me what the price is. In this stock, the fundamental factors are quite clear and evident for the next year, and that is all one needs to consider if one wants the most possible gain.
- ·11 t sittenFrom Tekinvestor. People must take into account that Circio, until the completed emission in January, lived on student loans and a diet based on oatmeal and noodles. Only a couple of months have passed now where the company has shifted gears due to better financial leeway. In that regard, it will be particularly interesting to see what the company will present at ASGTC, as it still represents what the company has generated in new knowledge and data from the period of weak economy. So people can themselves ponder what can come ahead now that they can increase the pace of CircVec's development. Say what you will, but what Circio has achieved in recent years strongly impresses me. What they can accomplish with good finances and more hands is something to look forward to…
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt